Literature DB >> 17370332

Cirrhosis after orthotopic liver transplantation in the absence of primary disease recurrence.

Moataz Seyam1, James M Neuberger, Bridget K Gunson, Stefan G Hübscher.   

Abstract

Liver allograft cirrhosis is a relatively uncommon complication of liver transplantation. Most cases can be attributed to disease recurrence, particularly recurrent hepatitis C. Little is known about the frequency, etiology, and natural history of liver allograft cirrhosis occurring without evidence of recurrent disease. The aim of the present study was to review the clinicopathological features in this group of patients. We retrospectively reviewed data from all adult patients who were transplanted between 1982 and 2002 and survived >12 months after orthotopic liver transplantation (n = 1,287). Cases of histologically proven cirrhosis were identified from histopathological data entered into the Liver Unit Database. A total of 48 patients (3.7%) developed cirrhosis. In 29 of them, cirrhosis could be attributed to recurrent disease (hepatitis C, 11; hepatitis B, 4; autoimmune hepatitis, 4; primary biliary cirrhosis, 2; primary sclerosing cholangitis, 3; nonalcoholic steatohepatitis, 4; alcoholic liver disease, 1). In 9 of the 19 patients without evidence of disease recurrence, another cause of cirrhosis could be identified (de novo autoimmune hepatitis, 4; biliary complications, 4; acquired hepatitis B, 1). In the remaining 10 cases, the cause of cirrhosis remained unknown; their previous biopsies had shown features of chronic hepatitis of uncertain etiology. Three patients in this group died, and the remaining 7 are alive with good graft function 3-12 years after cirrhosis was first diagnosed. The prevalence of "cryptogenic" posttransplant cirrhosis was significantly higher in patients initially transplanted for fulminant seronegative hepatitis (6%) than in those transplanted for other diseases (0.3%). In conclusion, posttransplant cirrhosis without disease recurrence is uncommon, but it is more frequent in patients transplanted for fulminant seronegative hepatitis. Chronic hepatitis is the most frequent underlying pathological process in cases where the cause of cirrhosis remains uncertain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17370332     DOI: 10.1002/lt.21060

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  6 in total

1.  Incidence of Recurrent NASH-Related Allograft Cirrhosis.

Authors:  Shelly Kakar; Mohannad Dugum; Ricardo Cabello; Abhinav Humar; Jawad Ahmad; Shahid M Malik
Journal:  Dig Dis Sci       Date:  2018-12-17       Impact factor: 3.199

Review 2.  Clinical features and management of autoimmune hepatitis.

Authors:  Edward-L Krawitt
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

Review 3.  Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-05-06       Impact factor: 3.199

Review 4.  Long-term liver allograft fibrosis: A review with emphasis on idiopathic post-transplant hepatitis and chronic antibody mediated rejection.

Authors:  Mukul Vij; Ashwin Rammohan; Mohamed Rela
Journal:  World J Hepatol       Date:  2022-08-27

5.  Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study.

Authors:  Gwilym J Webb; Thomas Marjot; Jonathan A Cook; Costica Aloman; Matthew J Armstrong; Erica J Brenner; Maria-Andreea Catana; Tamsin Cargill; Renumathy Dhanasekaran; Ignacio García-Juárez; Hannes Hagström; James M Kennedy; Aileen Marshall; Steven Masson; Carolyn J Mercer; Ponni V Perumalswami; Isaac Ruiz; Sarang Thaker; Nneka N Ufere; Eleanor Barnes; Alfred S Barritt; Andrew M Moon
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-08-28

Review 6.  COVID-19 and liver disease: mechanistic and clinical perspectives.

Authors:  Thomas Marjot; Gwilym J Webb; Alfred S Barritt; Andrew M Moon; Zania Stamataki; Vincent W Wong; Eleanor Barnes
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-03-10       Impact factor: 73.082

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.